Bustamante, Regine Fher S.

HRN: 21-22-80  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/12/2023
CEFUROXIME 750MG (VIAL)
10/12/2023
10/19/2023
IV
250mg
Q8hours
T/c UTI
Waiting Final Action 
10/14/2023
CEFTRIAXONE 1G (VIAL)
10/14/2023
10/21/2023
IV
800mg
OD
Sepsis
Waiting Final Action 
10/14/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/14/2023
10/21/2023
IV
80mg
Q8hours
Sepsis
Waiting Final Action 
10/16/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
10/16/2023
10/23/2023
IV
450mg
Q6hours
Sepsis
Waiting Final Action 
10/18/2023
CEFTRIAXONE 1G (VIAL)
10/18/2023
10/25/2023
IVTT
880mg
Q24
Bfs
Checking Final Appropriateness 
10/19/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/19/2023
10/26/2023
IVTT
43mg
Q8
Sepsis
Checking Final Appropriateness 
10/20/2023
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
10/20/2023
10/26/2023
TOPICAL
1
BID
Phlebitis
Checking Final Appropriateness 
10/20/2023
CEFTAZIDIME 1GM (VIAL)
10/20/2023
10/26/2023
IV
450mg
Q8h
Sepsis
Checking Final Appropriateness 
10/20/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
10/20/2023
10/26/2023
IV
65mg
Q6h
Sepsis
Checking Final Appropriateness 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: